ArticleESMO open2019
UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO).
Article in ESMO open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01993498 (A Prospective Cohort to Investigate Survivorship Issues in Patients With Early Cancer), which is not on this map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective Cohort to Investigate Survivorship Issues in Patients With Early Cancer
Who cites it
48 citing papers in PubMed.
- Return to work among self-employed breast cancer survivors from the CANTO cohort.Scientific reports · 2026Trial
- Insights adjusting for non-adherence in randomized clinical trials: a reanalysis of an adjuvant trial of tamoxifen duration in early breast cancer.British journal of cancer · 2023Trial
- Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Trial
- Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study.PLoS medicine · 2019Trial
- Research Study Attrition and Participant-Informed Retention Strategies Among Cancer Survivors.JAMA network open · 2026Article
- Prognostic value of lymphopenia in early breast cancer: learnings from the prospective CANTO cohort.Breast cancer research : BCR · 2026Article
- Article
- ATTITUDE - Addressing attrition in longitudinal cancer cohorts: an in-depth qualitative analysis of experiences and perspectives on participation in longitudinal studies among breast cancer survivors.Breast cancer research and treatment · 2026Observational
- Working conditions associated with return to work 2 years after breast cancer: insights from a cohort study.British journal of cancer · 2026Article
- Metabolomic profiling for predicting breast cancer treatment toxicities.Translational cancer research · 2025Article
- Long-term weight change among breast cancer patients treated with chemotherapy: a longitudinal study over 13 years.Breast cancer research : BCR · 2025Article
- Deep learning assessment of metastatic relapse risk from digitized breast cancer histological slides.Nature communications · 2025Article
- Article
- Observational
- Real-world safety and effectiveness of neoadjuvant chemotherapy combination with pembrolizumab in triple-negative breast cancer.ESMO real world data and digital oncology · 2024Article
- Dose/Exposure Relationship of Exercise and Distant Recurrence in Primary Breast Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Article
- Magnitude and Temporal Variations of Socioeconomic Inequalities in the Quality of Life After Early Breast Cancer: Results From the Multicentric French CANTO Cohort.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Article
- Cognition and Return to Work Status 2 Years After Breast Cancer Diagnosis.JAMA network open · 2024Article
- Inflammation at diagnosis and cognitive impairment two years later in breast cancer patients from the Canto-Cog study.Breast cancer research : BCR · 2024Article
- An effort to improve the collection of patient-generated data: readability and understandability of patient-reported outcomes measures in a survivorship cohort.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCorresponding with improved survival among patients with breast cancer, the awareness of the long-term effects of cancer treatments has increased. CANcer TOxicities (CANTO) aims to identify predictors of development and persistence of long-term toxicities in patients treated for stages I-III breast cancer and to characterise their incidence, as well their impact. In this paper, we describe the methodology used in this study and provide a first characterisation of the study population.
methodsCANTO (NCT01993498) is a French prospective, longitudinal cohort study enrolling patients with invasive cT0-cT3cN0-3M0 breast cancer of 26 French cancer centres. Patients are assessed at diagnosis, 3-6 (M0), 12 (M12), 36 (M36) and 60 (M60) months after completion of primary surgery, chemotherapy or radiotherapy whichever comes last. CANTO collects clinical, treatment, toxicity data, an extensive list of validated patient-reported outcomes (focusing on quality of life, psychological and behavioural questionnaires) and ad hoc socioeconomic questionnaires. Blood collection is performed at diagnosis, M0, M12, M36 and M60. Biologic sub-studies are ongoing (eg, microbiotic and cognitive sub-study).
resultsEnrolment started in 2012; by October 2018, 12 012 patients had been enrolled. Data collected have a low missing completion rate (<5% for key clinical variables, <20% for patient-reported outcomes). Blood, serum and plasma samples are stored in over 96% of patients. Among the first 5801 patients enrolled in CANTO, 76.7% of patients had hormone receptor positive and human epidermal growth factor 2 negative tumours; 73.1% of patients had breast conserving surgery; 90.4% received adjuvant radiotherapy, 53.4% (neo) adjuvant chemotherapy, 11.3% adjuvant trastuzumab and 80.3% adjuvant hormonotherapy.
conclusionsCANTO represents a unique opportunity to explore important medical, biological and psychosocial outcomes on breast cancer survivor population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.